OP010 Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years
William J. Sandborn(University of San Diego), Brian G. Feagan(Western University), C Gasink, Stephan R. Targan(Cedars-Sinai Medical Center), Jürgen M. Stein(Unknown), L-L Gao(Janssen (United States)), J F Colombel(European CanCer Organisation), Subrata Ghosh(University College Cork), P. Rutgeerts, Willem J.S. de Villiers(Stellenbosch University), Stephen B. Hanauer(Northwestern University), Jewel Johanns(Johnson & Johnson (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 13
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k